Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 160.9% in January

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 526,156 shares, a growth of 160.9% from the January 15th total of 201,697 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 481,087 shares, the short-interest ratio is presently 1.1 days. Based on an average trading volume of 481,087 shares, the short-interest ratio is presently 1.1 days. Currently, 0.3% of the shares of the stock are short sold.

Enlivex Therapeutics Stock Performance

Shares of ENLV traded up $0.01 during mid-day trading on Friday, reaching $1.11. The company had a trading volume of 108,200 shares, compared to its average volume of 426,519. The company has a market capitalization of $263.49 million, a price-to-earnings ratio of -2.02 and a beta of 1.63. The company’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $1.06. Enlivex Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.10.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. As a group, equities analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ENLV shares. Wall Street Zen cut Enlivex Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright raised their target price on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. Finally, D. Boral Capital reiterated a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.00.

Institutional Investors Weigh In On Enlivex Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Enlivex Therapeutics by 99.4% in the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after purchasing an additional 156,336 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in shares of Enlivex Therapeutics during the third quarter worth about $241,000. HRT Financial LP increased its stake in shares of Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after buying an additional 135,198 shares during the period. Jane Street Group LLC increased its stake in shares of Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the period. Finally, Susquehanna International Group LLP bought a new position in Enlivex Therapeutics in the 3rd quarter valued at approximately $57,000. Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.